Alexion Pharmaceuticals (ALXN) Receives “Buy” Rating from Cowen
Cowen reiterated their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note published on Wednesday. Cowen currently has a $165.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Alexion Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, March 7th. Guggenheim began coverage on shares of Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a neutral rating and a $135.00 price target on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 12th. Morgan Stanley lifted their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an overweight rating in a report on Tuesday, February 12th. Finally, Credit Suisse Group reaffirmed a buy rating and issued a $156.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, January 22nd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $160.73.
Shares of ALXN stock opened at $136.09 on Wednesday. The company has a market cap of $30.41 billion, a P/E ratio of 19.19, a price-to-earnings-growth ratio of 1.00 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.48 and a current ratio of 2.88. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $140.77.
In other news, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $126.00, for a total transaction of $252,000.00. Following the completion of the sale, the chief accounting officer now directly owns 5,020 shares in the company, valued at $632,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ludwig Hantson sold 3,244 shares of Alexion Pharmaceuticals stock in a transaction on Monday, December 31st. The stock was sold at an average price of $95.85, for a total transaction of $310,937.40. Following the sale, the chief executive officer now owns 150,696 shares of the company’s stock, valued at $14,444,211.60. The disclosure for this sale can be found here. Insiders sold 8,488 shares of company stock worth $873,875 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.
Several large investors have recently bought and sold shares of ALXN. Captrust Financial Advisors acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $31,000. NuWave Investment Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 851.9% during the fourth quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 460 shares during the period. Kaizen Advisory LLC lifted its stake in shares of Alexion Pharmaceuticals by 22.2% during the fourth quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 111 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $68,000. Finally, We Are One Seven LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth $79,000. Institutional investors and hedge funds own 93.24% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: No Load Funds
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.